Company

Lexaria Bioscience Corp. (LEXX)

Standardized SEC financial data for Lexaria Bioscience Corp. — income statement, balance sheet, cash flow and 40+ ratios, available as a clean JSON API. CIK 0001348362 · NASDAQ · Pharmaceutical Preparations.

Revenue growth (YoY)

52.0%

Return on equity

-457.3%

Free cash flow

-$10.5M

Current ratio

2.32×

EPS (diluted)

$-0.66

Ratios for fiscal year 2025, standardized from SEC filings.

Income statement

USD	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Revenue	$385K	$723K	$255K	$226K	$464K	$706K
Cost of revenue	$99K	$175K	$72K	$32K	$5K	$3K
Gross profit	$215K	$547K	$184K	$195K	$459K	$703K
R&D expense	$387K	$1.3M

Standardized from Lexaria Bioscience Corp.'s SEC filings — per-share figures split-adjusted. Full history via the API.

Balance sheet

USD	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Cash & equivalents	$1.3M	$10.9M	$5.8M	$1.4M	$6.5M	$1.8M
Inventory	$117K	$30K	$38K	$0	—	—
Total current assets	$1.9M	$12.4M	$7.0M	$2.2M	$7.9M

Cash flow

USD	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Operating cash flow	-$2.6M	-$4.0M	-$4.9M	-$5.9M	-$5.0M	-$10.5M
Capital expenditures	$0	—	$49K	$34K	$43K	$25K
Free cash flow	-$2.6M	—	-$4.9M	-$5.9M	-$5.0M

Get LEXX data via API

# JSON
curl https://sec-financial-api-production.up.railway.app/v1/company/LEXX/financials \
  -H "X-API-Key: YOUR_KEY"

# CSV export (income / balance / cash-flow)
curl "https://sec-financial-api-production.up.railway.app/v1/company/LEXX/income-statement?format=csv" \
  -H "X-API-Key: YOUR_KEY"

Get a free API key Use with Claude (MCP) →View LEXX filings on SEC EDGAR →